凯捷：2026生物制药研发的AI转型之路研究报告：战略选择、生存必需、抑或二者皆有？（英文版）（82页）.pdf

1、Make it real.Smart bet,only option,or both?Biopharma R&D turns to AI.Table of contents2Capgemini Research Institute 2026Smart bet,only option,or both?Biopharma R&D turns to AI.Executive summary04AI is the biopharma industrys prescription for ailing innovation 10Laying the groundwork for big bets on

2、AI in R&D22How AI is reshaping parts of the R&D value chain today30Insights from a senior biopharma leader at a global pharmaceutical company493Capgemini Research Institute 2026Smart bet,only option,or both?Biopharma R&D turns to AI.Conclusion 66Research methodology67Barriers to biopharma realizing

3、AIs potential50How biopharma organizations can accelerate and scale AI in R&D58Executive summary The pharmaceutical and biotechnology(biopharma)industry faces persistent,long-standing challenges to its R&D efficiency.Top among them are the high cost of drug development and elevated clinical failure

4、rates.The return on R&D investments has undergone a steady decline to a now flat,but unacceptable level,making it increasingly difficult to bring successful new drugs to market.AI is now emerging as a powerful catalyst for breakthroughs in R&D,precisely in the areas where the industry has struggled

5、most in recent years.By streamlining discovery,optimizing trial design,and enabling predictive insights,AI is poised to bring to biopharma R&D more agile,data-driven,and outcome-oriented processes.Converging technology including advances in biology,physics,and computational power are unlocking this

6、breakthrough now.Our global research reveals that biopharma organizations recognize this potential.It finds that 82%of executives believe AI will fundamentally transform biopharma R&D,and 60%agree that companies failing to scale AI will fall behind in innovation and market relevance.Executives also